John M. Goldberg

1.9k total citations · 1 hit paper
25 papers, 1.3k citations indexed

About

John M. Goldberg is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, John M. Goldberg has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in John M. Goldberg's work include Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and CAR-T cell therapy research (5 papers). John M. Goldberg is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and CAR-T cell therapy research (5 papers). John M. Goldberg collaborates with scholars based in United States, Canada and United Kingdom. John M. Goldberg's co-authors include Jeffrey Crawford, James Khatcheressian, Thomas J. Smith, Kari Bohlke, Gary H. Lyman, James L. Wade, Natasha B. Leighl, Kenneth R. Carson, Antoinette J. Wozniak and Jamés O. Armitage and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

John M. Goldberg

25 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

2015 589 citations Thomas J. Smith, Kari Bohlke et al. Journal of Clinical Oncology profile →

Peers

John M. Goldberg

ONCOL

PRM

PHEOH

GENET

B Andersson United States

Kurt W. Tauer United States

P.H.B. Willemse Netherlands

John H. Saiki United States

Eleanor V. Willett United Kingdom

Driss Chaoui France

Andrew Will United Kingdom

Nobuhiro Kanemura Japan

Polly Niravath United States

M Soukop United Kingdom

B Andersson United States

John M. Goldberg

478 ×0.7

ONCOL

214 ×0.8

PRM

208 ×0.9

PHEOH

211 ×1.0

153 ×0.8

GENET

Citations per year, relative to John M. Goldberg John M. Goldberg (= 1×) peers B Andersson

Countries citing papers authored by John M. Goldberg

Since Specialization

Citations

This map shows the geographic impact of John M. Goldberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Goldberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Goldberg more than expected).

Fields of papers citing papers by John M. Goldberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Goldberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Goldberg. The network helps show where John M. Goldberg may publish in the future.

Co-authorship network of co-authors of John M. Goldberg

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Goldberg. A scholar is included among the top collaborators of John M. Goldberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Goldberg. John M. Goldberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Falchook, Gerald S., Robert Wesolowski, Hatem Soliman, et al.. (2024). 658P First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors. Annals of Oncology. 35. S519–S519. 2 indexed citations

Kamgar, Mandana, Husain Yar Khan, Amro Aboukameel, et al.. (2024). Abstract CT080: A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma. Cancer Research. 84(7_Supplement). CT080–CT080. 3 indexed citations

Koru‐Sengul, Tulay, Gina Z. D’Amato, Matteo Trucco, et al.. (2021). Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.. Journal of Clinical Oncology. 39(15_suppl). 11542–11542. 4 indexed citations

Wilky, Breelyn A., Priya Kumthekar, Robert Wesolowski, et al.. (2018). Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy. Annals of Oncology. 29. viii416–viii417. 2 indexed citations

Wilky, Breelyn A., Priya Kumthekar, Robert Wesolowski, et al.. (2018). Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.. Journal of Clinical Oncology. 36(15_suppl). 3075–3075. 2 indexed citations

Wilky, Breelyn A. & John M. Goldberg. (2017). From vision to reality: deploying the immune system for treatment of sarcoma.. PubMed. 23(124). 61–74. 7 indexed citations

Wilky, Breelyn A., Priya Kumthekar, Robert Wesolowski, et al.. (2017). Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.. Journal of Clinical Oncology. 35(15_suppl). 3075–3075. 1 indexed citations

Goldberg, John M., et al.. (2015). Rhabdomyosarcoma in Adults: New Perspectives on Therapy. Current Treatment Options in Oncology. 16(6). 27–27. 47 indexed citations

Smith, Thomas J., Kari Bohlke, Gary H. Lyman, et al.. (2015). Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 33(28). 3199–3212. 589 indexed citations breakdown →

10.

Wilky, Breelyn A. & John M. Goldberg. (2014). Immunotherapy in sarcoma: a new frontier.. PubMed. 17(94). 201–6. 11 indexed citations

11.

Goldberg, John M., et al.. (2014). Extended Progression-Free Survival in Two Patients With Alveolar Soft Part Sarcoma Exposed to Tivantinib. Journal of Clinical Oncology. 32(34). e114–e116. 18 indexed citations

12.

Goldberg, John M.. (2013). Immunotherapy of sarcomas. Current Opinion in Oncology. 25(4). 390–397. 5 indexed citations

13.

Bregy, Amadé, et al.. (2013). Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treatment Reviews. 39(8). 891–907. 51 indexed citations

14.

Baird, Kristin, Denise K. Reinke, Joseph G. Pressey, et al.. (2013). A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.. Journal of Clinical Oncology. 31(15_suppl). TPS10591–TPS10591. 1 indexed citations

15.

Wagner, Andrew J., John M. Goldberg, Steven G. DuBois, et al.. (2012). Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors. Cancer. 118(23). 5894–5902. 118 indexed citations

16.

Goldberg, John M., Rebecca E. Scully, Stephen E. Sallan, & Steven E. Lipshultz. (2012). Cardiac Failure 30 Years After Treatment Containing Anthracycline for Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 34(5). 395–397. 7 indexed citations

17.

Goldberg, John M., et al.. (2012). Circulating myeloid-derived suppressor cells in pediatric solid tumor patients.. Journal of Clinical Oncology. 30(15_suppl). 9565–9565. 1 indexed citations

18.

Dillmon, Melissa S., John M. Goldberg, Suresh S. Ramalingam, et al.. (2012). Clinical Practice Guidelines for Cancer Care: Utilization and Expectations of the Practicing Oncologist. Journal of Oncology Practice. 8(6). 350–353. 12 indexed citations

19.

Zurier, Robert B., Ronald G. Rossetti, Joan H. Lane, et al.. (1998). Dimethylheptyl-THC-11 OIC acid: A nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis & Rheumatism. 41(1). 163–170. 87 indexed citations

20.

Zurier, Robert B., Ronald G. Rossetti, Joan H. Lane, et al.. (1998). Dimethylheptyl‐THC‐11 OIC acid: A nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis & Rheumatism. 41(1). 163–170. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact